bRIGHT procedural clipping strategy presented at PCR LV 2025 by X. Freixa
The data confirm the durable safety and effectiveness of the TriClip TEER in more than 511 patients treated in the real-world setting.
Related Resources
Valvular Heart Disease Guidelines at a Glance
Demonstrated Outcomes. Life-Changing Intervention
Reduced HF Hospitalisation. Improved Quality of Life
Immediate Relief. Durable Benefits
Tri.Fr 2 years outcomes
Navitor 5-years data from CRT
Tendyne expanded clinical study | PCR LV 2025
EXPAND G4 clinical data release | PCR LV 2025